{"transactions":[{"id":1294209,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-27T18:07:17.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":80300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":80300,"derivative":{"exercise_price":11.14,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":80300},"source":{"system":"sec-edgar","filing":"0001746473-25-000015","document":"wk-form4_1738019230.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000174647325000015/wk-form4_1738019230.xml","form_type":"4"}},{"id":1294208,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-01-27T18:07:17.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":40150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":251708,"source":{"system":"sec-edgar","filing":"0001746473-25-000015","document":"wk-form4_1738019230.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000174647325000015/wk-form4_1738019230.xml","form_type":"4"}},{"id":1297218,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-01-22T18:02:33.000Z","date":"2025-01-17","kind":"sale","planned":true,"acquired":false,"shares":15936,"price":11.2011,"value":178500.7296,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $11.03 to $11.695, inclusive, on January 17, 2025 and January 21, 2025 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":211558,"source":{"system":"sec-edgar","filing":"0001746473-25-000004","document":"wk-form4_1737586946.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000174647325000004/wk-form4_1737586946.xml","form_type":"4"}},{"id":1455150,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-07-12T18:41:16.000Z","date":"2024-07-10","kind":"sale","planned":true,"acquired":false,"shares":9900,"price":11.56,"value":114444.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $10.785 to $12.58, inclusive, between July 10, 2024 and July 11, 2024 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":227494,"source":{"system":"sec-edgar","filing":"0001746473-24-000127","document":"wk-form4_1720824069.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000174647324000127/wk-form4_1720824069.xml","form_type":"4"}},{"id":1455845,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-07-11T16:58:42.000Z","date":"2024-07-09","kind":"grant","planned":false,"acquired":true,"shares":19337,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2022, the Reporting Person was granted 70,312 performance-vested stock units, the vesting of which were subject to the achievement of various pre-established performance criteria. On July 9, 2024, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index, resulting in the vesting of 19,337 shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,488 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program."}],"balance_after":237394,"source":{"system":"sec-edgar","filing":"0001746473-24-000117","document":"wk-form4_1720731516.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000174647324000117/wk-form4_1720731516.xml","form_type":"4"}},{"id":1671847,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-24T16:57:47.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":63000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":63000,"derivative":{"exercise_price":17.44,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":63000},"source":{"system":"sec-edgar","filing":"0001746473-24-000016","document":"wk-form4_1706133455.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000174647324000016/wk-form4_1706133455.xml","form_type":"4"}},{"id":1671846,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-01-24T16:57:47.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":31500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":216569,"source":{"system":"sec-edgar","filing":"0001746473-24-000016","document":"wk-form4_1706133455.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000174647324000016/wk-form4_1706133455.xml","form_type":"4"}},{"id":1674948,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2024-01-19T17:19:21.000Z","date":"2024-01-17","kind":"sale","planned":true,"acquired":false,"shares":9786,"price":17.23,"value":168612.78,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $16.33 to $17.90, inclusive,  between January 17, 2024 and January 18, 2024 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":185069,"source":{"system":"sec-edgar","filing":"0001746473-24-000004","document":"wk-form4_1705702751.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000174647324000004/wk-form4_1705702751.xml","form_type":"4"}},{"id":1813631,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock (Right to Buy)","published_at":"2023-08-07T20:50:54.000Z","date":"2023-08-04","kind":"exercise","planned":true,"acquired":false,"shares":8791,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On January 24, 2019, the Reporting Person was granted stock options, the vesting of which was subject to the achievement of pre-established performance criteria which were achieved, and all of which were subject to the Reporting Person's continuous service to the Issuer."}],"balance_after":31367,"derivative":{"exercise_price":2.08,"expiration_date":"2028-03-31","underlying":"Common Stock","underlying_shares":8791},"source":{"system":"sec-edgar","filing":"0001209191-23-044892","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000120919123044892/doc4.xml","form_type":"4"}},{"id":1813630,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock (Right to Buy)","published_at":"2023-08-07T20:50:54.000Z","date":"2023-08-03","kind":"exercise","planned":true,"acquired":false,"shares":1800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"On January 24, 2019, the Reporting Person was granted stock options, the vesting of which was subject to the achievement of pre-established performance criteria which were achieved, and all of which were subject to the Reporting Person's continuous service to the Issuer."}],"balance_after":40158,"derivative":{"exercise_price":2.08,"expiration_date":"2028-03-31","underlying":"Common Stock","underlying_shares":1800},"source":{"system":"sec-edgar","filing":"0001209191-23-044892","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000120919123044892/doc4.xml","form_type":"4"}},{"id":1813629,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-08-07T20:50:54.000Z","date":"2023-08-04","kind":"sale","planned":true,"acquired":false,"shares":20050,"price":20.01,"value":401200.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 3, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.08, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4."}],"balance_after":194855,"source":{"system":"sec-edgar","filing":"0001209191-23-044892","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000120919123044892/doc4.xml","form_type":"4"}},{"id":1813628,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-08-07T20:50:54.000Z","date":"2023-08-04","kind":"exercise","planned":true,"acquired":true,"shares":8791,"price":2.08,"value":18285.28,"ownership":{"direct":true},"balance_after":214905,"source":{"system":"sec-edgar","filing":"0001209191-23-044892","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000120919123044892/doc4.xml","form_type":"4"}},{"id":1813627,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-08-07T20:50:54.000Z","date":"2023-08-03","kind":"sale","planned":true,"acquired":true,"shares":1800,"price":20,"value":36000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 3, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.08, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4."}],"balance_after":206114,"source":{"system":"sec-edgar","filing":"0001209191-23-044892","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000120919123044892/doc4.xml","form_type":"4"}},{"id":1813626,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-08-07T20:50:54.000Z","date":"2023-08-03","kind":"exercise","planned":true,"acquired":true,"shares":1800,"price":2.08,"value":3744.0,"ownership":{"direct":true},"balance_after":207914,"source":{"system":"sec-edgar","filing":"0001209191-23-044892","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000120919123044892/doc4.xml","form_type":"4"}},{"id":1813625,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-08-07T20:50:54.000Z","date":"2023-08-03","kind":"sale","planned":true,"acquired":false,"shares":13069,"price":20,"value":261380.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 3, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4."}],"balance_after":206114,"source":{"system":"sec-edgar","filing":"0001209191-23-044892","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000120919123044892/doc4.xml","form_type":"4"}},{"id":1826626,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-07-19T20:26:30.000Z","date":"2023-07-17","kind":"sale","planned":true,"acquired":false,"shares":17937,"price":18.0091,"value":323029.2267,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $17.63 to $18.47, inclusive, between July 17, 2023 and July 19, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":219183,"source":{"system":"sec-edgar","filing":"0001209191-23-042829","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000120919123042829/doc4.xml","form_type":"4"}},{"id":1827609,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-07-18T19:19:41.000Z","date":"2023-07-14","kind":"grant","planned":false,"acquired":true,"shares":35156,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2022, the Reporting Person was granted 70,312 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On July 14, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 35,156 shares."}],"balance_after":237120,"source":{"system":"sec-edgar","filing":"0001209191-23-042658","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000120919123042658/doc4.xml","form_type":"4"}},{"id":1931858,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-04-03T18:51:52.000Z","date":"2023-03-30","kind":"sale","planned":true,"acquired":false,"shares":9036,"price":26.5209,"value":239642.8524,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan established on behalf of the Reporting Person on July 28, 2022 in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $25.88 to $27.235, inclusive, on March 30, 2023 and March 31, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":201964,"source":{"system":"sec-edgar","filing":"0001209191-23-022369","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000120919123022369/doc4.xml","form_type":"4"}},{"id":1933745,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-03-31T17:59:57.000Z","date":"2023-03-29","kind":"grant","planned":false,"acquired":true,"shares":17578,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2022, the Reporting Person was granted 70,313 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On March 29,2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 17,578 shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,231 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program."}],"balance_after":211000,"source":{"system":"sec-edgar","filing":"0001209191-23-021919","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000120919123021919/doc4.xml","form_type":"4"}},{"id":2043471,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-27T19:15:36.000Z","date":"2023-01-25","kind":"grant","acquired":true,"shares":76200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":76200,"derivative":{"exercise_price":34.65,"expiration_date":"2033-01-24","underlying":"Common Stock","underlying_shares":76200},"source":{"system":"sec-edgar","filing":"0001140361-23-003180","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000114036123003180/form4.xml","form_type":"4"}},{"id":2043470,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2023-01-27T19:15:36.000Z","date":"2023-01-25","kind":"grant","acquired":true,"shares":54000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units that vest in three equal annual installments beginning January 16, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":192191,"source":{"system":"sec-edgar","filing":"0001140361-23-003180","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000114036123003180/form4.xml","form_type":"4"}},{"id":2078459,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2022-12-21T21:32:28.000Z","date":"2022-12-20","kind":"sale","acquired":false,"shares":8748,"price":19.1024,"value":167107.7952,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker at prices ranging from $18.4049 to $19.64, inclusive, on December 20, 2022 and December 21, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (3) to this Form 4."}],"balance_after":138191,"source":{"system":"sec-edgar","filing":"0001140361-22-046567","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000114036122046567/form4.xml","form_type":"4"}},{"id":2078458,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"officer":true,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2022-12-21T21:32:28.000Z","date":"2022-12-19","kind":"grant","acquired":true,"shares":17578,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2022, the Reporting Person was granted 70,313 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On December 19, 2022, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 17,578 shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,115 shares of Common Stock acquired by the Reporting Person pursuant to an employee stock purchase program."}],"balance_after":146939,"source":{"system":"sec-edgar","filing":"0001140361-22-046567","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000114036122046567/form4.xml","form_type":"4"}},{"id":2415803,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-02T20:14:26.000Z","date":"2022-01-26","kind":"grant","acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":112500,"derivative":{"exercise_price":11.86,"expiration_date":"2032-01-25","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0001567619-22-002399","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000156761922002399/doc1.xml","form_type":"4"}},{"id":2690694,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-05-28T19:58:58.000Z","date":"2021-05-26","kind":"exercise","acquired":false,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":12979,"derivative":{"exercise_price":2.08,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001209191-21-036690","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000120919121036690/doc4.xml","form_type":"4"}},{"id":2690693,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-05-28T19:58:58.000Z","date":"2021-05-26","kind":"exercise","acquired":true,"shares":4500,"price":2.08,"value":9360.0,"ownership":{"direct":true},"balance_after":125246,"source":{"system":"sec-edgar","filing":"0001209191-21-036690","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000120919121036690/doc4.xml","form_type":"4"}},{"id":2894748,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-26T20:00:10.000Z","date":"2021-01-23","kind":"grant","acquired":true,"shares":62250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":62250,"derivative":{"exercise_price":26.5,"expiration_date":"2031-01-22","underlying":"Common Stock","underlying_shares":62250},"source":{"system":"sec-edgar","filing":"0000899243-21-003380","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000089924321003380/doc4.xml","form_type":"4"}},{"id":2924922,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-04T20:00:08.000Z","date":"2020-12-30","kind":"exercise","acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":17479,"derivative":{"exercise_price":2.08,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0000899243-21-000219","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000089924321000219/doc4.xml","form_type":"4"}},{"id":2924921,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-01-04T20:00:08.000Z","date":"2020-12-30","kind":"exercise","acquired":true,"shares":3500,"price":2.08,"value":7280.0,"ownership":{"direct":true},"balance_after":120746,"source":{"system":"sec-edgar","filing":"0000899243-21-000219","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000089924321000219/doc4.xml","form_type":"4"}},{"id":3115797,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Series C Preferred Stock","published_at":"2020-06-09T21:24:19.000Z","date":"2020-06-05","kind":"exercise","acquired":false,"shares":27322,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by The Sloger Hull Family Trust.  The Reporting Person and his spouse serve as trustees for the trust.  The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3821},"source":{"system":"sec-edgar","filing":"0000899243-20-015881","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000089924320015881/doc4.xml","form_type":"4"}},{"id":3115796,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Series B Preferred Stock","published_at":"2020-06-09T21:24:19.000Z","date":"2020-06-05","kind":"exercise","acquired":false,"shares":36319,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series B Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series B Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series B Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5079},"source":{"system":"sec-edgar","filing":"0000899243-20-015881","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000089924320015881/doc4.xml","form_type":"4"}},{"id":3115795,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-06-09T21:24:19.000Z","date":"2020-03-31","kind":"grant","acquired":true,"shares":70352,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On May 22, 2020, the Issuer completed a one-for-7.15 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"shares","element":"transactionShares","label":"F3","text":"On May 22, 2020, the Issuer completed a one-for-7.15 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 31, 2020 (or if there is no corresponding day in any such month, on the last day of such month), subject to the Reporting Person's continuous service to the Issuer on each such date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"On May 22, 2020, the Issuer completed a one-for-7.15 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On May 22, 2020, the Issuer completed a one-for-7.15 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."}],"balance_after":70352,"derivative":{"exercise_price":6.22,"expiration_date":"2030-03-30","underlying":"Common Stock","underlying_shares":70352},"source":{"system":"sec-edgar","filing":"0000899243-20-015881","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000089924320015881/doc4.xml","form_type":"4"}},{"id":3115794,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Series C Preferred Stock","published_at":"2020-06-09T21:24:19.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":27322,"price":13.0845,"value":357494.709,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On May 22, 2020, the Issuer completed a one-for-7.15 reverse stock split of the Issuer's Common Stock (\"Reverse Stock Split\"). This amount has been adjusted to give effect to this Reverse Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by The Sloger Hull Family Trust.  The Reporting Person and his spouse serve as trustees for the trust.  The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":27322,"derivative":{"underlying":"Common Stock","underlying_shares":3821},"source":{"system":"sec-edgar","filing":"0000899243-20-015881","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000089924320015881/doc4.xml","form_type":"4"}},{"id":3115793,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-06-09T21:24:19.000Z","date":"2020-06-05","kind":"exercise","acquired":true,"shares":3821,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series C Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series C Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by The Sloger Hull Family Trust.  The Reporting Person and his spouse serve as trustees for the trust.  The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":3821,"source":{"system":"sec-edgar","filing":"0000899243-20-015881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000089924320015881/doc4.xml","form_type":"4"}},{"id":3115792,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":83857,"kind":"person","name":"Hull Hans","position":1,"cik":"0001614876","reported_name":"Hull Hans","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-06-09T21:24:19.000Z","date":"2020-06-05","kind":"exercise","acquired":true,"shares":5079,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering.  The Series B Preferred Stock converted into Common Stock on a 7.15-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock had no expiration date."}],"balance_after":117246,"source":{"system":"sec-edgar","filing":"0000899243-20-015881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614876/000089924320015881/doc4.xml","form_type":"4"}}]}